Praxbind (Idarucizumab)
Specific Reversal Agent for Dabigatran – Hospital Use Only
Quick Facts About Praxbind
Key Takeaways About Praxbind
- Specific dabigatran reversal: Praxbind is the only approved agent that specifically and completely reverses the anticoagulant effect of dabigatran (Pradaxa) within minutes of administration
- Hospital emergency use only: Praxbind is administered exclusively in hospital settings by healthcare professionals for emergency situations such as life-threatening bleeding or urgent surgery
- Rapid onset of action: Clinical studies demonstrated immediate and complete reversal of dabigatran’s effect in over 98% of patients, with normalisation of coagulation parameters within minutes
- No known direct side effects: Clinical trials have not identified any adverse effects directly caused by Praxbind, though thromboembolic events may occur due to the cessation of anticoagulation
- Resume anticoagulation promptly: After receiving Praxbind, patients should resume anticoagulant therapy as soon as medically appropriate to reduce thrombotic risk from the underlying condition
What Is Praxbind and What Is It Used For?
Praxbind (idarucizumab) is a humanised monoclonal antibody fragment that acts as a specific reversal agent for the anticoagulant dabigatran. It is used in hospital emergency settings to rapidly neutralise dabigatran’s blood-thinning effect when patients require urgent surgery or are experiencing life-threatening or uncontrolled bleeding.
Praxbind contains the active substance idarucizumab, a fragment of a monoclonal antibody produced using recombinant DNA technology. Idarucizumab binds to dabigatran with an affinity approximately 350 times greater than dabigatran’s affinity for thrombin, the coagulation factor that dabigatran inhibits. By capturing and neutralising free and thrombin-bound dabigatran molecules in the bloodstream, Praxbind effectively and immediately restores the body’s natural clotting ability.
Dabigatran (marketed as Pradaxa) is a direct oral anticoagulant (DOAC) widely prescribed to prevent stroke in patients with atrial fibrillation and to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). While dabigatran is highly effective at reducing the risk of blood clots, situations can arise where its anticoagulant effect must be urgently reversed. Before the development of Praxbind, there was no specific antidote for dabigatran, making emergency management of bleeding patients or those requiring urgent surgery considerably more challenging.
Praxbind is indicated for use in adult patients treated with dabigatran when rapid reversal of its anticoagulant effects is required in the following emergency situations:
- Emergency surgery or urgent procedures: When a patient on dabigatran requires an unplanned operation or invasive procedure that cannot be safely delayed, and adequate haemostasis is essential
- Life-threatening or uncontrolled bleeding: When a patient on dabigatran develops serious haemorrhage that cannot be controlled with standard supportive measures alone
The development of Praxbind represented a significant advance in the safety profile of dabigatran therapy. The pivotal RE-VERSE AD (Reversal Effects of Idarucizumab on Active Dabigatran) trial, a global Phase III study involving 503 patients, demonstrated that a single 5 g intravenous dose of idarucizumab achieved immediate and complete reversal of the anticoagulant effect of dabigatran in 100% of patients requiring urgent surgery and in 93.4% of patients with uncontrolled bleeding.
Praxbind is designed to reverse only dabigatran. It does not reverse the effects of any other anticoagulant, including warfarin, rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana), or heparins. For reversal of factor Xa inhibitors (rivaroxaban, apixaban, edoxaban), the specific reversal agent andexanet alfa (Ondexxya) may be considered. Warfarin is reversed using vitamin K and/or prothrombin complex concentrates (PCC).
What Should You Know Before Receiving Praxbind?
Praxbind is administered by healthcare professionals in emergency hospital settings. Before administration, your medical team will consider any allergies, hereditary fructose intolerance, and the risk of thromboembolic events after dabigatran reversal.
Because Praxbind is used exclusively in hospital emergency settings, the decision to administer it is made by your treating physician based on a careful assessment of the clinical situation. However, there are important considerations that the medical team will take into account, and that you or your family members should be aware of.
Contraindications
There are no absolute contraindications to the use of Praxbind in a life-threatening situation. However, your medical team should be informed if any of the following apply:
- Allergy to idarucizumab or any of the other ingredients in Praxbind (listed in the composition section below) – as with all biological medicines, allergic or hypersensitivity reactions are theoretically possible
- Hereditary fructose intolerance: The recommended dose of Praxbind contains 4 g of sorbitol as an excipient. In patients with hereditary fructose intolerance, sorbitol can cause serious adverse reactions. The potential benefit of emergency treatment must be carefully weighed against this risk
Warnings and Precautions
Several important clinical considerations apply when Praxbind is administered:
- Thrombotic risk after reversal: Patients taking dabigatran have underlying conditions (such as atrial fibrillation, venous thromboembolism, or mechanical heart valves) that place them at increased risk for blood clots. By reversing dabigatran’s anticoagulant effect, Praxbind removes this protection and exposes patients to the thrombotic risk of their underlying disease. Therefore, anticoagulant therapy should be resumed as soon as clinically appropriate after Praxbind administration
- Sorbitol content: Each 5 g dose of Praxbind contains approximately 4 g of sorbitol. Patients with hereditary fructose intolerance require extended medical monitoring during and for up to 24 hours after Praxbind administration
- Sodium content: Each dose contains 50 mg sodium (equivalent to 2.5% of the WHO recommended maximum daily intake for adults), which should be considered in patients on controlled-sodium diets
- Biological medicine: As a biological medicine derived from monoclonal antibody technology, Praxbind carries a theoretical risk of immunogenic reactions, although no such reactions were observed in clinical trials
The treating physician will ensure that the batch number of Praxbind administered is documented in the patient’s medical records to enable traceability, as required for all biological medicines.
Pregnancy and Breastfeeding
There are no clinical data on the use of Praxbind in pregnant or breastfeeding women. As Praxbind is a monoclonal antibody fragment that does not directly affect any physiological body functions, but solely binds to and neutralises dabigatran, the physician may decide to administer it if the expected benefits to the mother outweigh any potential risks. In a life-threatening emergency where Praxbind is clinically indicated, the benefit of treatment is expected to outweigh any theoretical risk.
It is not known whether idarucizumab is excreted in human breast milk. Given the emergency nature of treatment and the short half-life of the drug (approximately 45 minutes), any potential exposure through breast milk is expected to be minimal and transient.
Children and Adolescents
There is no information available on the use of Praxbind in children and adolescents under 18 years of age. Dabigatran is not approved for use in paediatric populations in most countries, so the need for its reversal agent in this population is extremely rare. If reversal of dabigatran is required in a paediatric patient, the treating physician will make an individual risk–benefit assessment.
Other Medications
Praxbind has been specifically designed to bind only to dabigatran and its acyl glucuronide metabolites. It is unlikely to interact with other medicines. Praxbind does not bind to or affect other anticoagulants, antiplatelet agents, or any other class of medication. Tell your healthcare team about all medications you are currently taking, as this information is important for overall clinical management, even though Praxbind itself is not expected to cause drug interactions.
How Does Praxbind Interact with Other Drugs?
Praxbind is highly specific for dabigatran and is not expected to have clinically meaningful interactions with other medications. It does not affect other anticoagulants, antiplatelet agents, or any other class of drugs.
One of the most important advantages of Praxbind is its remarkable specificity. Idarucizumab was engineered to bind exclusively to dabigatran and its metabolites, with no binding affinity for thrombin, other coagulation factors, or other medicines. This means that Praxbind will not interfere with any other medications a patient is taking at the time of administration.
Formal drug interaction studies have not identified any clinically significant interactions between idarucizumab and other medicinal products. This is consistent with the highly specific mechanism of action: idarucizumab captures dabigatran molecules without affecting any other pharmacological targets in the body.
Important Clinical Considerations
| Medication Class | Examples | Interaction with Praxbind | Clinical Note |
|---|---|---|---|
| Other anticoagulants | Warfarin, rivaroxaban, apixaban, edoxaban, heparins | None – Praxbind does not reverse these drugs | If reversal of another anticoagulant is needed, a different reversal strategy is required |
| Antiplatelet agents | Aspirin, clopidogrel, ticagrelor, prasugrel | None – Praxbind does not affect platelet function | Platelet function remains unaffected; manage bleeding from antiplatelet agents separately |
| Thrombolytics | Alteplase, tenecteplase, streptokinase | None expected | Praxbind does not interfere with fibrinolytic therapy |
| Procoagulant agents | Tranexamic acid, PCC, rFVIIa | None expected | Praxbind can be used alongside supportive haemostatic measures |
| IV infusion solutions | Normal saline (0.9% NaCl) | Compatible | IV line must be flushed with 0.9% NaCl before and after Praxbind administration; do not mix with other medicines |
Although Praxbind itself does not interact with other medications, the clinical context in which it is used requires careful management of the patient’s complete medication regimen. After Praxbind administration, the patient’s anticoagulation status will change dramatically, and the medical team will need to consider when and how to reinitiate anticoagulation therapy.
After Praxbind has been given, dabigatran therapy can be restarted 24 hours later if the patient is clinically stable and adequate haemostasis has been achieved. Alternatively, a different antithrombotic agent (such as low-molecular-weight heparin) can be started at any time if the patient is stable and haemostasis is adequate. The timing of anticoagulation resumption is a critical clinical decision that balances the risk of re-bleeding against the risk of thromboembolic events.
What Is the Correct Dosage of Praxbind?
The recommended dose is 5 g (two vials of 2.5 g/50 ml each), administered intravenously as two consecutive infusions over 5–10 minutes each, or as a bolus injection. Praxbind is given exclusively in hospitals by trained healthcare professionals.
Praxbind is not a medication that patients administer themselves. It is given exclusively in hospital settings by physicians and nurses trained in emergency medicine. The dosing regimen is straightforward and standardised to facilitate rapid administration in time-critical situations.
Adults
Standard Dose – Emergency Reversal of Dabigatran
Dose: 5 g intravenously (two vials of 2.5 g/50 ml each)
Administration: Two consecutive intravenous infusions, each lasting 5–10 minutes, or as a single bolus injection of both vials
The 5 g dose provides immediate and complete reversal of dabigatran’s anticoagulant effect. No dose adjustment is required based on patient weight, age, sex, or renal function.
Second Dose (Rare Situations)
Dose: An additional 5 g may be considered if clinically indicated
A second dose may be warranted in the following circumstances:
- Recurrence of clinically relevant bleeding with prolonged coagulation times
- Potentially life-threatening new bleeding with prolonged coagulation times
- Need for a second emergency surgery or urgent procedure with prolonged coagulation times
Relevant coagulation tests used to assess dabigatran activity and the need for additional dosing include the activated partial thromboplastin time (aPTT), dilute thrombin time (dTT), and ecarin clotting time (ECT). These specialised tests help the medical team determine whether dabigatran remains active in the patient’s blood.
Method of Administration
Praxbind is administered intravenously only. The two 50 ml vials (containing 2.5 g each) can be given by either of two methods:
- Two consecutive infusions: Each vial is infused over 5–10 minutes through a pre-existing intravenous line or through a separate line
- Bolus injection: Both vials are injected as a bolus, which may be preferred in the most time-critical emergency situations
An existing intravenous line can be used for administration, but it must be flushed with 0.9% sodium chloride solution before and after the infusion. No other medicines should be administered simultaneously through the same intravenous line.
Children and Adolescents
No dosing information is available for paediatric patients. Praxbind has not been studied in patients under 18 years of age. In the rare event that dabigatran reversal is needed in a paediatric patient, the treating physician will make an individual clinical decision.
Elderly Patients
No dose adjustment is required in elderly patients. The standard 5 g dose is used regardless of age. In the pivotal RE-VERSE AD trial, the median age of patients was 78 years, confirming the efficacy and safety of the standard dose in the elderly population.
Patients with Renal Impairment
No dose adjustment is required for patients with renal impairment. Although idarucizumab is partially eliminated through the kidneys, the emergency context and single-dose nature of Praxbind treatment means that dose modification based on renal function is not necessary. Importantly, patients with impaired renal function tend to have higher dabigatran levels, making the availability of a specific reversal agent particularly valuable in this population.
Overdose
A maximum daily dose of Praxbind has not been formally established. In clinical trials, doses of up to 8 g were administered without any additional safety concerns. In the event that a dose exceeding the recommended 5 g is administered, the patient should be monitored clinically. There is no specific antidote for idarucizumab, and the drug is not removed by dialysis.
What Are the Side Effects of Praxbind?
No specific side effects directly attributable to Praxbind have been identified in clinical trials. The main safety concern is the risk of thromboembolic events (blood clots) that may occur after dabigatran reversal due to the patient’s underlying prothrombotic condition.
Like all medicines, Praxbind can potentially cause side effects, although the clinical evidence to date has been remarkably reassuring. In the pivotal RE-VERSE AD trial and post-marketing surveillance, no adverse effects have been directly attributed to idarucizumab itself. The adverse events observed in patients receiving Praxbind were related to the underlying medical conditions that necessitated its use, rather than to the drug itself.
It is important to understand that in the emergency settings where Praxbind is used, patients are typically critically ill or injured. This makes it inherently difficult to distinguish drug-related adverse events from those caused by the underlying condition. The medical team will monitor you closely throughout and after treatment.
The most significant risk associated with Praxbind use is the occurrence of thromboembolic events (blood clots) after dabigatran reversal. These events are not caused by Praxbind directly but result from the removal of anticoagulation in patients who have underlying conditions that predispose them to blood clot formation. In the RE-VERSE AD trial, thromboembolic events occurred in approximately 6.3% of patients within 90 days after Praxbind administration, which is consistent with the thrombotic risk expected in this critically ill patient population.
No Identified Side Effects
Based on clinical trial data (RE-VERSE AD, n=503)
- No adverse drug reactions directly attributable to idarucizumab have been identified to date
- As a biological medicine, allergic or hypersensitivity reactions (e.g. pruritus, bronchospasm, skin rash, anaphylaxis) are theoretically possible but have not been reported in clinical studies
- Fever, delirium, and constipation were observed in some patients, but were attributed to the underlying medical conditions rather than to Praxbind
Risk of Thromboembolic Events After Reversal
The most clinically significant concern following Praxbind administration is the risk of thromboembolic complications. Patients who receive dabigatran do so because they have conditions that increase their risk of blood clots, such as atrial fibrillation, deep vein thrombosis, or pulmonary embolism. By reversing dabigatran’s anticoagulant effect, Praxbind restores the patient’s pre-treatment clotting status, which means they are once again at risk for the thromboembolic events that dabigatran was prescribed to prevent.
In clinical studies, the following thromboembolic events were reported within 90 days of Praxbind administration: deep vein thrombosis, pulmonary embolism, ischaemic stroke, systemic embolism, and myocardial infarction. Most of these events occurred in patients who had not yet resumed anticoagulant therapy. This underscores the importance of restarting anticoagulation as soon as the patient’s clinical condition permits.
Reporting Suspected Side Effects
If you or a family member experience any unexpected symptoms after receiving Praxbind, it is important to inform the treating medical team immediately. Healthcare professionals are encouraged to report suspected adverse reactions through their national pharmacovigilance reporting system. In the European Union, reports can be submitted through the national competent authority of each member state, while in the United States, reports can be submitted to the FDA MedWatch programme. Ongoing monitoring of post-marketing safety data helps ensure the continued safe use of this medicine.
How Should Praxbind Be Stored?
Praxbind is stored in hospital pharmacies under refrigerated conditions (2–8°C), protected from light, and must not be frozen. Unopened vials can be kept at room temperature (up to 30°C) for a maximum of 48 hours.
Praxbind storage is managed entirely by hospital pharmacy and clinical staff. As a patient, you will not be responsible for storing this medication. However, the following information is important for understanding how the quality and efficacy of the product are maintained:
- Refrigerated storage: Praxbind must be stored at 2–8°C in a refrigerator, in its original packaging to protect it from light
- Do not freeze: Freezing can damage the protein structure of idarucizumab and must be avoided
- Room temperature allowance: Before use, the unopened vial can be stored at room temperature (up to 30°C) for a maximum of 48 hours, provided it is kept in the original carton to protect it from light
- After opening: Chemical and physical in-use stability has been demonstrated for up to 6 hours at room temperature (up to 30°C). However, the solution should ideally be used immediately after opening
- Light exposure: Total light exposure should not exceed 6 hours (combined time in unopened and opened vials)
- Shelf life: The expiry date is printed on the vial and carton. Do not use after the last day of the stated month
- Single-use only: Praxbind vials are for single use only and do not contain preservatives. Any unused solution must be discarded
The solution should be clear to slightly opalescent and colourless to slightly yellow. Do not use if the solution is discoloured, contains particles, or appears otherwise abnormal.
What Does Praxbind Contain?
Each vial of Praxbind contains 2.5 g of idarucizumab in 50 ml of solution (50 mg/ml). Inactive ingredients include sodium acetate trihydrate, acetic acid, sorbitol, polysorbate 20, and water for injections.
Active Ingredient
The active substance is idarucizumab, a humanised monoclonal antibody fragment (Fab fragment) produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology. Each 50 ml vial contains 2.5 g of idarucizumab, giving a concentration of 50 mg/ml. The complete therapeutic dose consists of two vials (5 g total).
Idarucizumab has a molecular weight of approximately 47.8 kDa. It is derived from a murine monoclonal antibody that has been humanised to reduce immunogenicity. The Fab fragment retains the antigen-binding site that recognises and binds dabigatran with extremely high affinity (dissociation constant approximately 2.1 pM), while lacking the Fc region that mediates immune effector functions. This design ensures that idarucizumab neutralises dabigatran without triggering significant immune-mediated side effects.
Inactive Ingredients (Excipients)
| Excipient | E Number | Function |
|---|---|---|
| Sodium acetate trihydrate | E262 | Buffer – maintains solution pH |
| Acetic acid | E260 | pH adjustment |
| Sorbitol | E420 | Stabiliser – protects protein structure (4 g per dose) |
| Polysorbate 20 | E432 | Surfactant – prevents protein aggregation |
| Water for injections | – | Solvent |
Packaging
Praxbind is supplied as a clear to slightly opalescent, colourless to slightly yellow solution in Type I glass vials closed with butyl rubber stoppers and aluminium caps. Each carton contains two vials, together providing the complete therapeutic dose of 5 g idarucizumab. The glass vials and rubber stoppers are compatible with standard intravenous infusion equipment made of polyvinyl chloride, polyethylene, polyurethane, and polypropylene.
Frequently Asked Questions About Praxbind
Praxbind (idarucizumab) is a specific antidote for the blood-thinning medication dabigatran (Pradaxa). If you are taking dabigatran and experience a serious bleeding episode or need emergency surgery, Praxbind can be given to you in hospital to rapidly reverse the blood-thinning effect. It works within minutes and allows your blood to clot normally again, so that emergency medical treatment can proceed safely.
Praxbind works extremely quickly. In clinical studies, a single 5 g dose achieved immediate and complete reversal of dabigatran’s anticoagulant effect within minutes of intravenous administration. Coagulation parameters such as the dilute thrombin time (dTT) and ecarin clotting time (ECT) returned to normal levels almost immediately. This rapid onset of action is crucial in emergency situations where every minute counts.
No. Praxbind is designed to reverse only dabigatran (Pradaxa). It has no effect on other anticoagulants such as warfarin, rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana), or heparins. Each anticoagulant requires a different reversal approach. For example, warfarin is reversed with vitamin K and prothrombin complex concentrates, while andexanet alfa (Ondexxya) may be used for factor Xa inhibitors.
Clinical studies have not identified any side effects that are directly caused by Praxbind. The main concern after receiving Praxbind is the increased risk of blood clots (thromboembolic events), but this is due to the removal of dabigatran’s blood-thinning protection rather than a side effect of Praxbind itself. Your medical team will monitor you closely and will restart anticoagulation therapy as soon as it is safe to do so.
Yes. Dabigatran therapy can be restarted 24 hours after receiving Praxbind, provided you are clinically stable and adequate blood clotting has been achieved. If earlier anticoagulation is needed, a different blood thinner such as low-molecular-weight heparin can be started sooner. Your doctor will decide on the best timing and choice of anticoagulant based on your individual clinical situation and the reason Praxbind was given.
RE-VERSE AD (Reversal Effects of Idarucizumab on Active Dabigatran) was the pivotal Phase III clinical trial that led to Praxbind’s approval. This global, multicentre, prospective study enrolled 503 patients across 173 sites in 39 countries. The study demonstrated that Praxbind achieved immediate, complete, and sustained reversal of dabigatran in patients requiring emergency surgery (Group A) or experiencing uncontrolled/life-threatening bleeding (Group B). The results were published in the New England Journal of Medicine in 2017.
References
This article is based on the following peer-reviewed sources and authoritative guidelines:
- Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. N Engl J Med. 2017;377(5):431–441. doi:10.1056/NEJMoa1707278
- European Medicines Agency (EMA). Praxbind (idarucizumab) – Summary of Product Characteristics (SmPC). Last updated November 2024.
- Levy JH, Ageno W, Chan NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(3):623–627.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373–498.
- Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. J Am Coll Cardiol. 2020;76(5):594–622.
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List (2023). Geneva: World Health Organization.
- Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386(9994):680–690.
- Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019;380(14):1326–1335.
Medical Editorial Team
This article was written by the iMedic Medical Editorial Team and reviewed by specialists in haematology, emergency medicine, and clinical pharmacology. Our editorial process follows international guidelines including the WHO, EMA, ESC, and ISTH recommendations.
All medical information is based on Level 1A evidence: systematic reviews and meta-analyses of randomised controlled trials, supplemented by regulatory authority guidance (EMA SmPC, FDA prescribing information).
iMedic maintains complete editorial independence. We have no commercial funding, no pharmaceutical sponsorship, and no advertising. Our content is reviewed and updated regularly to reflect the latest evidence.